Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients
- PMID: 25386089
- PMCID: PMC4223274
- DOI: 10.3748/wjg.v20.i41.15387
Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients
Abstract
Aim: To investigate the impact of spleen operation (SO) on interferon-α (IFN-α)-based antiviral treatment in patients with hepatitis C virus (HCV)-related cirrhosis.
Methods: Studies were systematically identified by searching electronic databases including MEDLINE, Cochrane Library, Elsevier, and Embase up to September 30, 2013, and relevant clinical studies were reviewed. Sustained virological response (SVR) rate and adherence to therapy were taken as the endpoints of interest.
Results: A total of 603 patients from 16 studies were included in the systematic review. Of 372 patients who underwent SO followed by antiviral treatment, the total SVR rate was 39.5%. SVR was associated with HCV genotypes 2/3 (OR = 10.84; 95%CI: 5.47-21.47; P < 0.00001). IFN-α dose needed to be reduced in 29.4%, and IFN-α-based therapy was discontinued in 11.5% of patients. Analysis of controlled studies showed that SVRs were achieved in 34.1% of patients with SO and 31.1% of patients without SO. SO had no effect on the SVR rate in cirrhotic patients with genotype 1 HCV infection (OR = 1.28; 95%CI: 0.51-3.22; P = 0.60), but improved the SVR rate in patients with genotypes 2/3 infection, though the difference was not significant (OR = 0.36; 95%CI: 0.13-1.02; P = 0.05).
Conclusion: SO combined with IFN-α-based antiviral therapy may be suitable in cirrhotic patients with genotypes 2/3 HCV infection, but not in those with genotype 1 infection.
Keywords: Hepatitis C virus cirrhosis; Interferon, Ribavirin; Partial splenic embolization; Splenectomy.
Figures





Similar articles
-
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.Health Technol Assess. 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. Health Technol Assess. 2011. PMID: 21473834 Free PMC article.
-
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390. Health Technol Assess. 2004. PMID: 15461877
-
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 13;3(3):CD011644. doi: 10.1002/14651858.CD011644.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2018 Dec 03;12:CD011644. doi: 10.1002/14651858.CD011644.pub3. PMID: 28285495 Free PMC article. Updated.
-
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280. Health Technol Assess. 2006. PMID: 16904047
-
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.Cochrane Database Syst Rev. 2014 Feb 28;2014(2):CD005441. doi: 10.1002/14651858.CD005441.pub3. Cochrane Database Syst Rev. 2014. PMID: 24585509 Free PMC article.
Cited by
-
Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.PLoS One. 2017 Oct 5;12(10):e0184654. doi: 10.1371/journal.pone.0184654. eCollection 2017. PLoS One. 2017. PMID: 28981513 Free PMC article.
References
-
- Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21, vii. - PubMed
-
- Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46. - PubMed
-
- Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296–305. - PubMed
-
- Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472. - PubMed
-
- Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–398, vi. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical